VALENCIA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2008 third quarter financial results on
Wednesday, November 5, 2008 at 8:00 a.m. EST.
Management of the Company will host a conference call to discuss the third
quarter financial results, clinical progress and other Company developments at
9:00 a.m. EST on November 5, 2008. Presenting from the Company will be its
Chairman and Chief Executive Officer, Alfred Mann; President and Chief
Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial
Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific
Officer, Peter Richardson.
To participate in the live call by telephone, please dial (888) 677-5721
or (210) 839-8507. Those interested in listening to the conference call live
via the Internet may do so by visiting the Company's website at
http://www.mannkindcorp.com.
A telephone replay of the call will be accessible for approximately
fourteen days following completion of the call by dialing (866) 411-1707 or
(202) 369-0654. A replay will also be available on MannKind's website for
fourteen days.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development
and commercialization of therapeutic products for patients with diseases such
as diabetes and cancer. Its pipeline includes AFRESA(TM), which has completed
Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical
trials. Both of these investigational products are being evaluated for their
safety and efficacy in the treatment of diabetes. For more information on
MannKind Corporation and its technology, visit http://www.mannkindcorp.com.
SOURCE MannKind Corporation
